People With HIV Have High Burden of HIV-Associated Neurocognitive Disorder
People with HIV, particularly patients in sub-Saharan Africa and Latin America, have a high burden of HIV-associated neurocognitive disorder.
HIV/AIDS
Combination Interventions Needed to Tackle Excess Mortality From Extramedical Opioids
Excess mortality occurred as the result of a number of causes, including overdose, injuries, and both infectious and noncommunicable diseases.
Neurocognitive Conditions Among People Living With HIV
Neurologic conditions associated with HIV remain major contributors to morbidity and mortality, and are increasingly recognized in the aging population of individuals living with HIV.
Discontinuation of Dolutegravir Due to Neurologic Side Effects Linked to Pre-Existing Mental Illness
Dolutegravir (DTG) discontinuation due to neuropsychologic side effects (NPS) may be associated with pre-existing psychiatric conditions of depression and anxiety.
Telmisartan Adjunct Treatment May Reduce CNS Inflammation During Acute HIV
Telmisartan did not affect biomarkers of central nervous system inflammation or injury when used as an adjunct to ART for acute HIV infection.
Surveillance Estimates Prevalence of Neural Tube Defects in Births to Women With HIV
The prevalence of neural tube defects (NTDs) in births to mothers with HIV from 2013 to 2017 was estimated to be 7.0 per 10,000 live births.
Prevelance of Neural Tube Defect in HIV-Exposed Individuals
The prevalence of neural tube defects (NTDs) is 7.0 per 10,000 live births in HIV-exposed pregnancies, which is similar to the prevalence in the general population.
Prevalence of HIV-Associated Distal Sensory Peripheral Neuropathy in Resource-Limited Settings
Although the prevalence of distal sensory peripheral neuropathy decreased following initiation of cART in people living with in resource-limiting settings, better strategies are needed.
Fetal Exposure to Efavirenz May Increase Risk for Microcephaly
In utero exposure to efavirenz is associated with an increased risk for microcephaly among children who are HIV-exposed but uninfected.
Updated Labeling for Efavirenz-Containing Products Warns of Possible Late-Onset Neurotoxicity
The Warnings and Precautions section has been updated to address the potential for late-onset neurotoxicity, including ataxia and encephalopathy with efavirenz treatment.
- Loading...
Loading...
Next post in General Neurology
Loading... 
Loading...